Rheumatoid Arthritis vs Lupus (SLE) — Clinical Trial Comparison
Rheumatoid Arthritis
Joint-centred autoimmune disease
Lupus (SLE)
Systemic multi-organ autoimmune disease
Both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are autoimmune conditions where the immune system attacks the body. While they share some treatments — particularly biologics and immunosuppressants — their clinical trial landscapes differ significantly in scope, focus, and eligibility.
Key Differences at a Glance
| Feature | Rheumatoid Arthritis | Lupus (SLE) |
|---|---|---|
| Primary target | Synovial joints | Multiple organs (skin, kidneys, brain, joints, blood) |
| Key biomarkers | RF, Anti-CCP, CRP, ESR, HLA-DRB1 | Anti-dsDNA, ANA, Complement C3/C4, Anti-Sm |
| Diagnosis | ACR/EULAR classification criteria | ACR/EULAR criteria (different scoring) |
| Disease measurement | DAS28 score | SLEDAI-2K or BILAG score |
| Common complications | Joint deformity, cardiovascular disease | Lupus nephritis, CNS lupus, antiphospholipid syndrome |
| Organ involvement | Joints primarily | Kidneys, brain, heart, lungs, skin, blood |
Clinical Trial Availability
| Trial Aspect | Rheumatoid Arthritis | Lupus (SLE) |
|---|---|---|
| UK trials actively recruiting | 60–100 studies | 15–30 studies |
| Most common trial phase | Phase 2–3 | Phase 2–3 |
| Top drug classes tested | Biologics, JAK inhibitors, biosimilars | Biologics (belimumab, anifrolumab), immunosuppressants |
| Biosimilar trials | Very common | Rare |
| Biomarker-driven trials | Common (seropositive vs seronegative) | Growing (type I IFN signature, complement) |
| Paediatric trial availability | Moderate (JIA trials) | Limited (childhood-onset SLE) |
Treatment Approaches in Current Trials
Shared Treatment Classes
- JAK inhibitors — tofacitinib, upadacitinib, baricitinib (approved for RA; trials for lupus)
- Anti-CD20 therapy — rituximab used in both, though more evidence in RA
- Conventional immunosuppressants — methotrexate, azathioprine, mycophenolate
- Hydroxychloroquine — used in both, trials focus on optimisation
RA-Specific Trial Treatments
- Anti-TNF agents (adalimumab, etanercept, infliximab) — biosimilar trials
- Anti-IL-6 agents (tocilizumab, sarilumab)
- T-cell co-stimulation modulators (abatacept)
- B-cell depletion strategies
- Treat-to-arget optimisation studies
Lupus-Specific Trial Treatments
- BAFF inhibitors (belimumab) — first lupus-specific biologic approved
- Type I interferon receptor antagonists (anifrolumab)
- Lupus nephritis-specific protocols (mycophenolate vs cyclophosphamide)
- Complement inhibitors for renal involvement
- Anti-CD38 and plasma cell targeting
💡 Lupus nephritis: A specialised trial pathway
Up to 60% of lupus patients develop kidney involvement. Lupus nephritis has its own set of clinical trials with specific eligibility criteria, endpoints (proteinuria reduction, renal response), and treatment approaches. If you have lupus nephritis, search specifically for these trials rather than general SLE studies.
Eligibility Differences
RA Trial Criteria
- Seropositive (RF+ or anti-CCP+) vs seronegative status matters for some trials
- DAS28 score thresholds define disease activity requirements
- DMARD-naive vs DMARD-IR vs biologic-IR determines treatment line
- Many trials exclude patients with concurrent other autoimmune diseases
- Joint imaging (X-ray, ultrasound) may be required at screening
Lupus Trial Criteria
- SLEDAI-2K score required (usually ≥4 or ≥6 for active trials)
- Organ involvement may qualify or exclude — lupus nephritis trials need renal biopsy
- Complement levels (C3, C4) and anti-dsDNA used as biomarkers
- Background medication requirements (must be on stable hydroxychloroquine)
- Pregnancy prevention is critical — many lupus trials require contraception
🦴 Rheumatoid Arthritis Trials
Find actively recruiting RA clinical trials across the UK
View RA TrialsNot sure which autoimmune condition applies?
Our Smart Matcher can help find trials based on your symptoms and test results.
Open Smart Matcher